Figure 5.

The effects of Fn and cFn on the expression of PADI4 and RANKL in FLSs isolated from RA or OA patients. RA or OA FLSs were treated with Fn or cFn at 2 μg/ml for 72 h, the relative mRNA levels of PADI4 and RANKL were detected by RT-PCR (upper panels), and the protein level of PADI4 and RANKL were detected by Western blot analysis (lower panels). RA (n = 8) and OA (n = 6). cFn, citrullinated fibronectin; FLSs, fibroblast-like synoviocytes; Fn, fibronectin; OA, osteoarthritis; PADI4, peptidylarginine deiminase type 4; RA, rheumatoid arthritis; RANKL, receptor activator of nuclear factor kappa B ligand; RT-PCR, reverse transcriptase polymerase chain reaction.